Foscarbidopa
| Drug Information | |||
|---|---|---|---|
| Image | 
| ||
| Identifiers
ChEBI
|
Chemical Data
| ||
Foscarbidopa is a pharmaceutical compound used primarily in the treatment of Parkinson's disease. It is a prodrug of carbidopa, designed to enhance the delivery and efficacy of carbidopa in the central nervous system. Foscarbidopa is often used in combination with levodopa, another medication that is a precursor to dopamine, to improve the management of Parkinson's disease symptoms.
Mechanism of Action[edit | edit source]
Foscarbidopa works by inhibiting the enzyme aromatic L-amino acid decarboxylase (AADC) in the peripheral tissues. This inhibition prevents the premature conversion of levodopa to dopamine outside the brain, allowing more levodopa to reach the central nervous system where it can be converted to dopamine. Dopamine is a critical neurotransmitter that is deficient in patients with Parkinson's disease.
Pharmacokinetics[edit | edit source]
Foscarbidopa is absorbed in the gastrointestinal tract and converted to carbidopa in the body. The conversion allows for a more sustained release and prolonged action of carbidopa, enhancing its therapeutic effects. The bioavailability of foscarbidopa is influenced by factors such as food intake and the presence of other medications.
Clinical Use[edit | edit source]
Foscarbidopa is used in combination with levodopa to treat the motor symptoms of Parkinson's disease, such as tremors, rigidity, and bradykinesia. By increasing the availability of levodopa in the brain, foscarbidopa helps to improve the quality of life for patients with Parkinson's disease.
Side Effects[edit | edit source]
Common side effects of foscarbidopa include nausea, dizziness, and headache. More serious side effects can include dyskinesia, hallucinations, and orthostatic hypotension. Patients should be monitored for these adverse effects, and dosage adjustments may be necessary.
Research and Development[edit | edit source]
Foscarbidopa is currently under investigation in various clinical trials to assess its efficacy and safety in different populations and in combination with other therapeutic agents. Ongoing research aims to optimize its use and explore potential new indications.
Also see[edit | edit source]
Template:Parkinson's disease treatment
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
